TOM SHARMA - 21 Mar 2023 Form 4 Insider Report for INTEGRAL AD SCIENCE HOLDING CORP. (IAS)

Role
Chief Product Officer
Signature
/s/ Anil Sukumaran by Power of Attorney
Issuer symbol
IAS
Transactions as of
21 Mar 2023
Net transactions value
-$177,178
Form type
4
Filing time
23 Mar 2023, 17:32:15 UTC
Previous filing
17 Jun 2022
Next filing
27 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IAS Common Stock, $0.001 par value Options Exercise $36,036 +4,200 $8.58 4,200 21 Mar 2023 Direct
transaction IAS Common Stock, $0.001 par value Sale $58,800 -4,200 -100% $14.00 0 21 Mar 2023 Direct F1, F2
transaction IAS Common Stock, $0.001 par value Options Exercise $243,543 +28,385 $8.58 28,385 22 Mar 2023 Direct
transaction IAS Common Stock, $0.001 par value Sale $397,958 -28,385 -100% $14.02 0 22 Mar 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IAS Options (Right to Buy) Options Exercise $0 -4,200 -1.4% $0.000000 287,396 21 Mar 2023 Common Stock, $0.001 par value 4,200 $8.58 Direct F1, F4
transaction IAS Options (Right to Buy) Options Exercise $0 -28,385 -9.9% $0.000000 259,011 22 Mar 2023 Common Stock, $0.001 par value 28,385 $8.58 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.01 per share. The reporting person undertakes to provide toIntegral Ad Science Holding Corp., any security holder of Integral Ad Science Holding Corp. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number ofshares sold at each separate price within the range set forth herein.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.10 per share. The reporting person undertakes to provide toIntegral Ad Science Holding Corp., any security holder of Integral Ad Science Holding Corp. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number ofshares sold at each separate price within the range set forth herein.
F4 These options were granted on November 2, 2020 and vest 25% after one year and in equal quarterly installments over the next three years.